VIVO - Meridian Bioscience, Inc.
| Previous Close | 9.62 |
| Open | 9.62 |
| Bid | 9.50 x 1800 |
| Ask | 9.51 x 900 |
| Day's Range | 9.45 - 9.64 |
| 52 Week Range | 7.63 - 17.71 |
| Volume | 163,252 |
| Avg. Volume | 398,106 |
| Market Cap | 408.144M |
| Beta (5Y Monthly) | 0.38 |
| PE Ratio (TTM) | 16.72 |
| EPS (TTM) | 0.57 |
| Earnings Date | Feb 06, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 31, 2019 |
| 1y Target Est | 9.00 |
- GlobeNewswire
Meridian Launched a New High-Fidelity Polymerase to Offer Robust Amplification for NGS and PCR Applications
CINCINNATI, Jan. 23, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of a High-Specificity Pfu HS Mix that not only provides high-fidelity.
- Simply Wall St.
Do You Like Meridian Bioscience, Inc. (NASDAQ:VIVO) At This P/E Ratio?
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
- GlobeNewswire
Meridian Bioscience to Hold First Quarter 2020 Financial Results Conference Call on February 7, 2020
CINCINNATI, Jan. 15, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter 2020.
- GuruFocus.com
A Duo of Underperforming Stocks to Ease
Sell-side anaysts also recommend selling shares of these companies Continue reading...
- Simply Wall St.
Is There An Opportunity With Meridian Bioscience, Inc.'s (NASDAQ:VIVO) 22% Undervaluation?
In this article we are going to estimate the intrinsic value of Meridian Bioscience, Inc. (NASDAQ:VIVO) by taking the...
- Insider Monkey
Meridian Bioscience, Inc. (VIVO): Are Hedge Funds Right About This Stock?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- American City Business Journals
Multimillion-dollar settlement proposed in lawsuit over stock price at one of region’s largest public companies
A hearing has been scheduled in federal court in Cincinnati so a judge can determine whether to approve a proposed $2.1 million settlement in a class-action lawsuit filed against Meridian Bioscience following dips in the firm’s stock price in 2017.
- Thomson Reuters StreetEvents
Edited Transcript of VIVO earnings conference call or presentation 7-Nov-19 3:00pm GMT
Q4 2019 Meridian Bioscience Inc Earnings Call
- Zacks
Meridian Bioscience (VIVO) Q4 Earnings and Revenues Surpass Estimates
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 44.44% and 1.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Meridian Bioscience Reports Fourth Quarter and Full-Year Fiscal 2019 Operating Results and Provides Fiscal 2020 Guidance
CINCINNATI, Nov. 07, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2019. Fourth.
- GlobeNewswire
Meridian submits Curian™ analyzer and the Curian™ HpSA assay to the FDA
CINCINNATI, Nov. 06, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has submitted Curian™ and the Curian™ HpSA assay to the FDA for review. This.
- Simply Wall St.
Is Meridian Bioscience (NASDAQ:VIVO) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- Zacks
Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Is Meridian Bioscience, Inc. (VIVO) Going to Burn These Hedge Funds?
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees during the first half of 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a […]
- GlobeNewswire
Meridian Bioscience to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on November 7, 2019
CINCINNATI, Oct. 16, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report fourth quarter and.
- Simply Wall St.
How Many Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares Have Insiders Sold, In The Last Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- Simply Wall St.
Boasting A 14% Return On Equity, Is Meridian Bioscience, Inc. (NASDAQ:VIVO) A Top Quality Stock?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- Zacks
Should Value Investors Pick Meridian Bioscience (VIVO) Now?
Let's see if Meridian Bioscience (VIVO) stock is a good choice for value-oriented investors right now from multiple angles.
- Thomson Reuters StreetEvents
Edited Transcript of VIVO earnings conference call or presentation 30-Jul-19 2:00pm GMT
Q3 2019 Meridian Bioscience Inc Earnings Call
Motley FoolMeridian Bioscience Inc (VIVO) Q3 2019 Earnings Call Transcript
VIVO earnings call for the period ending June 30, 2019.
- Zacks
Meridian Bioscience (VIVO) Beats Q3 Earnings Estimates
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 60.00% and -2.76%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Meridian Bioscience Reports Third Quarter 2019 Operating Results
CINCINNATI, Ohio, July 30, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter and first nine months ended June 30, 2019..
- GlobeNewswire
Meridian Bioscience to Hold Third Quarter 2019 Financial Results Conference Call on July 30, 2019
CINCINNATI, July 10, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report third quarter 2019.
CNW GroupInMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors
OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis technology for cannabinoid-based pharmaceuticals to treat severe diseases, today announced the appointment of Catherine Sazdanoff , JD, to its Board of Directors. Ms. Sazdanoff joins InMed's Board with 35 years of experience in the healthcare industry.
